StreetInsider.com News Articles

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Tue, 03 Mar 2026 08:00:00 -0500

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark.

The presentations will highlight clinical data supporting buntanetap's treatment effect in PD with a particular focus on cognition and biomarker findings, and provide an update on the ongoing pivotal

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Tue, 03 Mar 2026 08:00:00 -0500

The presentations will highlight clinical data supporting buntanetap's treatment effect in PD with a particular focus on cognition and biomarker findings, and provide an update on the ongoing pivotal

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Tue, 03 Mar 2026 08:00:00 -0500

The presentations will highlight clinical data supporting buntanetap's treatment effect in PD with a particular focus on cognition and biomarker findings, and provide an update on the ongoing pivotal

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Tue, 03 Mar 2026 08:00:00 -0500

The presentations will highlight clinical data supporting buntanetap's treatment effect in PD with a particular focus on cognition and biomarker findings, and provide an update on the ongoing pivotal

Form 8-K Annovis Bio, Inc. For: Feb 12

Thu, 12 Feb 2026 09:01:00 -0500

si-local-file:///var/storage/secattach/20260212/25988421.html

Form 8-K Annovis Bio, Inc. For: Feb 12

Thu, 12 Feb 2026 09:01:00 -0500

si-local-file:///var/storage/secattach/20260212/25988421.html

Annovis receives safety board approval for Alzheimer's drug trial

Thu, 12 Feb 2026 08:00:23 -0500

Annovis Bio Inc. (NYSE: ANVS) announced that an independent Data and Safety Monitoring Board has recommended continuation of the company's pivotal Phase 3 clinical trial of buntanetap for Alzheimer's disease without modification.

The monitoring board reviewed six-month safety data and concluded that no safety concerns were identified. The safety profile observed in Alzheimer's patients was consistent with data from Parkinson's disease patients at the same timepoint, according to the company's statement.

The Phase 3 Alzheimer's trial is currently 40% complete with patient recruitment ongoing across the United States. Annovis expects the first symptomatic efficacy readout in early 2027, followed by a disease-modifying

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

Thu, 12 Feb 2026 08:00:00 -0500

MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that an independent Data and Safety Monitoring Board (DSMB) has issued a positive recommendation regarding the safety of buntanetap at 6 months, supporting the continuation of the ongoing pivotal Phase 3 AD clinical trial without modification.

The DSMB is responsible for periodically reviewing accumulated safety data and providing independent recommendations on the conduct and

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

Thu, 12 Feb 2026 08:00:00 -0500

The DSMB is responsible for periodically reviewing accumulated safety data and providing independent recommendations on the conduct and

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

Thu, 12 Feb 2026 08:00:00 -0500

The DSMB is responsible for periodically reviewing accumulated safety data and providing independent recommendations on the conduct and

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

Thu, 12 Feb 2026 08:00:00 -0500

The DSMB is responsible for periodically reviewing accumulated safety data and providing independent recommendations on the conduct and

Form 8-K Annovis Bio, Inc. For: Jan 28

Wed, 28 Jan 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260128/25909131.html

Form 8-K Annovis Bio, Inc. For: Jan 28

Wed, 28 Jan 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260128/25909131.html

Annovis Bio to launch extension study for Parkinson's drug buntanetap

Thu, 18 Dec 2025 16:35:49 -0500

Annovis Bio Inc. (NYSE: ANVS) announced plans to begin an open-label extension study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson's disease patients.

The study aims to enroll 500 patients across multiple sites in the United States for a 36-month treatment period with once-daily 30mg oral buntanetap. The trial will include two cohorts: former participants of buntanetap clinical studies and patients receiving deep brain stimulation treatment.

The first cohort will allow the company to evaluate how patient outcomes evolved after discontinuing treatment and assess responses when treatment is reintroduced. The second cohort will include patients who

Annovis Bio to launch extension study for Parkinson's drug buntanetap

Thu, 18 Dec 2025 16:35:49 -0500

Annovis Bio Inc. (NYSE: ANVS) announced plans to begin an open-label extension study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson's disease patients.

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will begin an Open-Label Extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in PD patients.

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Thu, 18 Dec 2025 16:35:00 -0500

Enrollment will begin in January 2026

Participants will be treated with buntanetap for 36 months

The study aims to enroll 500 patients

“Launching the OLE study is a